COMMUNIQUÉS West-GlobeNewswire

Orion receives award for international growth from the President of the Republic of Finland
14/11/2025
ORION CORPORATION PRESS RELEASE 14 NOVEMBER 2025 at 13.30 EET Orion receives award for international growth from the President of the Republic of Finland Today, the President of the Republic of Finland, Alexander Stubb [...]
Teleflex to Present at the Jefferies Global Healthcare Conference in London
14/11/2025
WAYNE, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) is scheduled to speak at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025, at 10:00 a.m. ( [...]
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results
14/11/2025
Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc. Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate [...]
Picard Reports Third Quarter 2025 Financial Results
14/11/2025
– Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence – TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of [...]
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
14/11/2025
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin [...]
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
14/11/2025
Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor outcomes [...]
Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery
14/11/2025
Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery CoTx-101 represents a potential breakthrough for patients with retinal [...]
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
14/11/2025
New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancers GVHD trial launching through non-dilutive funding from NIH- [...]
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
14/11/2025
BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients [...]
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
14/11/2025
Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company’s Alzheimer's Disease clinical trial results NEW YORK, Nov. 14, 2025 ( [...]
Paragon Genomics Introduces New CleanPlex® NGS Panel for Pharmacogenomics Profiling at AMP 2025
14/11/2025
--Simple, Accurate, Affordable Solution for Pharmacogenomics Profiling to Identify Genetic Biomarkers Associated with Drug Response-- --Learn More About the Paragon Genomics CleanPlex ® NGS Panel at AMP 2025 Booth # 432 [...]
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
14/11/2025
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatment Expects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026 Granted NIH SBIR award to advance influenza A/B [...]
Lifeward Ltd. Reports Third Quarter 2025 Financial Results
14/11/2025
Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non [...]
Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe
14/11/2025
Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Privé Jacques Cartier MASSY for lung cancer screening applications PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “ [...]
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
14/11/2025
WALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today [...]
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
14/11/2025
Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Demonstrated continued best-in- [...]
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
14/11/2025
NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best [...]
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
14/11/2025
Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although statistical [...]

Pages